Baird Financial Group Inc. Buys New Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Baird Financial Group Inc. has acquired a new stake in Jazz Pharmaceuticals PLC, purchasing 4,341 shares valued at approximately $539,000 in the first quarter of the year.
• Jazz Pharmaceuticals reported a loss of ($8.25) earnings per share last quarter, missing analyst estimates, despite generating revenues of $1.05 billion, which met expectations.
• Research analysts have given Jazz Pharmaceuticals a strong outlook, with multiple price targets increased, including Goldman Sachs raising its target to $185.00 and Needham setting a target of $202.00.

Baird Financial Group Inc. bought a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,341 shares of the specialty pharmaceutical company's stock, valued at approximately $539,000.

A number of other large investors have also modified their holdings of JAZZ. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at $25,000. Elequin Capital LP raised its stake in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares in the last quarter. Picton Mahoney Asset Management raised its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Finally, Spire Wealth Management raised its stake in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $126.90 on Thursday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The firm has a market cap of $7.70 billion, a PE ratio of -18.86, a price-to-earnings-growth ratio of 7.97 and a beta of 0.24. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The business has a fifty day moving average of $117.88 and a 200-day moving average of $116.88.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter last year, the business posted $5.30 earnings per share. The business's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. The Goldman Sachs Group increased their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a research note on Friday, August 29th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Morgan Stanley increased their price objective on Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday, August 28th. Truist Financial increased their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research note on Thursday, August 28th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Fourteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $178.67.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.